Q32 Bio is a clinical-stage biotechnology company based in Cambridge, Mass., developing biologic therapeutics to restore healthy immune regulation by targeting regulators of the innate and adaptive immune systems. Its lead programs target the IL-7R pathway (ADX-914) and the complement system (ADX-097). ADX-914 is a fully human anti-IL-7R antibody in a first-in-human trial designed to evaluate safety, tolerability and demonstrate proof-of-mechanism. ADX-097 is a fusion protein from Q32’s tissue-targeted complement regulation platform and was expected to enter Phase 1 in Q4 2021. The company is led by CEO Michael Broxson and intends to use new funds to advance ADX-914 through proof-of-mechanism, further develop its complement platform, and expand its platform and pipeline. Q32 Bio is a Cambridge, Massachusetts-based biotechnology company developing treatments for patients with severe autoimmune and inflammatory diseases. The company focuses on biologics designed to restore healthy immune regulation, including a monoclonal antibody antagonist of the interleukin-7 receptor (IL-7R). It also operates a complement therapeutics platform that has generated fusion proteins to downregulate complement activity specifically in disease-affected tissues. Q32 Bio's most advanced program, ADX-914, is a fully human anti-IL-7R antibody licensed from Bristol Myers Squibb that aims to re-regulate adaptive immune function. The company was seeded and incubated by Atlas Venture and builds on foundational science from researchers at the University of Colorado and the Medical University of South Carolina. Q32 Bio is led by CEO and co-founder Michael Broxson and CSO and President of Research Shelia Violette, Ph.D.

Total raised

$106M

Funding rounds

2

Latest round

Series B

Latest activity

Nov 2020